Thermo fisher scientific announces fda clearance of breakthrough immunoassays to aid in the risk assessment of preeclampsia

Waltham, mass.--(business wire)--thermo fisher scientific inc. (nyse: tmo), the world leader in serving science, today announced that the u.s. food and drug administration (fda) has cleared the thermo scientific b·r·a·h·m·s plgf plus kryptor and b·r·a·h·m·s sflt-1 kryptor novel biomarkers, the first and only immunoassays to receive breakthrough designation and clearance for the risk assessment and clinical management of preeclampsia, a severe pregnancy complication. preeclampsia is a life-threa.
TMO Ratings Summary
TMO Quant Ranking